3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Classical hematology
1
Conditions
Colorectal Neoplasms
4
Venous Thromboembolism
2
Thrombocythemia, Essential
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Ovarian Neoplasms
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Hemorrhage
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms, Hereditary Nonpolyposis
1
Breast Neoplasms
1
Interventions
Etoposide
4
Cisplatin
4
lutetium Lu 177 dotatate
2
fludarabine phosphate
2
fludarabine
2
Cyclophosphamide
2
Bleomycin
2
repotrectinib
1
pegfilgrastim
1
etoposide phosphate
1
copper dotatate CU-64
1
Watchful Waiting
1
Vorinostat
1
Teniposide
1
Surveys and Questionnaires
1
Standard of Care
1
Specimen Handling
1
Respiratory Physiological Phenomena
1
Practice Guidelines as Topic
1
Platinum
1
Nivolumab
1
Mesna
1
Magnetic Resonance Spectroscopy
1
Lutetium-177
1
Lutetium
1
Injections
1
Immunotherapy
1
Filgrastim
1
Drug Therapy
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms, Germ Cell and Embryonal
×
Aspirin
×
Clear all
NCT06866964
2026-02-02
ASPIRE
Wake Forest University Health Sciences
Phase 2
Recruiting
35 enrolled